Your participation in the Parkinson’s Disease Biomarkers Program will provide important contributions to the identification of biomarkers for PD and/or related disorders, as well as to the future development of treatments that will slow down the progression of these diseases. To date, a total of 5019 individuals have been enrolled in the PDBP.
The ultimate goal for the treatment of Parkinson's disease (PD) is to develop disease-modifying treatments that slow, prevent, or reverse the underlying disease process.
Participants share their biomarker study experiences.
Listen to first hand accounts of men and women who have participated in studies.